Kisunla
(Donanemab)Phase 3Monoclonal antibody
Eli LillyKisunla is a monoclonal antibody that works as Amyloid Beta N3pg Inhibitor.[2] It is being investigated across 5 indications, with its most advanced program in Phase 3.[1]
Kisunla is one of 74 monoclonal antibody programs targeting Alzheimer disease. It is currently in Phase 3.
5
Indications
16
Total Trials
11
Active Trials
73
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
171 competitors in Alzheimer Disease
#DrugCompanyPhaseTrials
1Tirazone
SanofiPhase 3
Kisunla
Eli LillyPhase 3
Karxt
Bristol-Myers SquibbPhase 3
Karx-EC
Bristol-Myers SquibbPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Aricept
EisaiPhase 2
Naproxen Sodium
BayerPhase 3
Namenda
AbbViePhase 2
Exelon
NovartisPhase 2
Depo-Provera
Eli LillyPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alzheimer's Disease7 trials
Preclinical Alzheimer's Disease2 trials
ART2 trials
Alzheimer disease2 trials
2 more indications
Amyloid1 trial
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
Not yet recruiting·—·Phase 4·NCT06911944·60 enrolled
Cognitive Dysfunction1 trial
Regulatory
FDA Approval Timeline[4]
Jul 2, 2024
KISUNLA
BLA BLA761248
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Donanemab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]